John Riddick, MD
Interventional Cardiology · Nashville, TNNPI 1417131715
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (30.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 40.8% of the total. Reporting peaked in 2021 at $18,119 and has fallen 91.7% since, to $1,501 in 2025.
Across 236 payments — averaging $197.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$19K
- Medtronic$18K
- Abbott$6K
- Boston Scientific$2K
- Abiomed$1K
- Shockwave Medical, Inc$498
- plus $756 from 11 others
Across 66 payments — averaging $3652.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$139K
- Edwards Lifesciences$102K
What the payments were for
- Consulting fees$14,10030%
- Speaking & faculty fees$14,10030%
- Travel & lodging$8,25718%
- Food & beverage$10,22622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 52 | $19,028 |
| Medtronic(2 entities) | 38 | $17,845 |
| Abbott | 55 | $5,809 |
| Boston Scientific | 46 | $1,719 |
| Abiomed | 8 | $1,027 |
| Shockwave Medical, Inc | 6 | $498 |
| Inari Medical, Inc. | 4 | $214 |
| Pfizer | 12 | $204 |
| Amgen | 6 | $161 |
| Cardiac Dimensions, Inc. | 2 | $50 |
| Novo Nordisk | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Spectrawave, Inc | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$17,024
- CoreValve Evolut$8,766
- COREVALVE EVOLUT R$8,063
- Mitra Clip system$2,346
- Impella$933
- Tendyne Mitral Valve System$652
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$397
- Tricuspid Valve Repair System$281
- GENERAL - THERAPIES$269
- Vascular Lithotripsy$231
- PORTICO$214
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$203
- MitraClip$179
- WATCHMAN Access System$174
- EVERA MRI XT DR SURESCAN$173
- PASCAL$170
- Xience Xpedition coronary stent system$156
- FlowTriever$156
- ClotTriever$156
- AMPLATZER TALISMAN$150
How this compares
$46,683 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $139,104 |
| FarxigaDapagliflozin Propanediol | 34 | $32,069 |
| XareltoRivaroxaban | 34 | $30,034 |
| Atorvastatin Calcium | 222 | $2,607 |
| ClopidogrelClopidogrel Bisulfate | 157 | $2,339 |
| Losartan Potassium | 110 | $1,523 |
| Icosapent Ethyl | 11 | $1,395 |
| Carvedilol | 155 | $1,332 |
| Metoprolol Succinate | 88 | $1,047 |
| Rosuvastatin Calcium | 59 | $857 |
| Ezetimibe | 19 | $766 |
| Lisinopril | 64 | $656 |
| Amlodipine Besylate | 91 | $450 |
| Furosemide | 97 | $389 |
| Potassium Chloride | 30 | $381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $139,104154 claims |
| AstraZenecaFarxiga | $15 | $32,06934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Nashville
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Samuel HorrNashville$246K
- Colin BarkerNashville$217K
- Leah RajNashville$88K
- Andrew GoodmanNashville$57K
- Jay PatelNashville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.